Patients with dual-positive (Ro52+/Ro60+) antibodies exhibited the most severe disease phenotype, characterized by higher disease activity, more frequent systemic complications, and a significantly increased risk of developing difficult-to-treat RA (D2T-RA). Here, TRIM21 is linked to rheumatoid arthritis.